Skip to main content

LENZ Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 19, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 19, 2025

LENZ$4.29+22.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LENZ THERAPEUTICS, INC.
By:/s/ Evert Schimmelpennink
Name:Evert Schimmelpennink
Title:Chief Executive Officer
(Principal Executive Officer)
By:/s/ Daniel Chevallard
Name:Daniel Chevallard
Title:Chief Financial Officer
(Principal Financial and Accounting Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Evert Schimmelpennink and Daniel Chevallard, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Evert SchimmelpenninkChief Executive Officer, President and DirectorMarch 19, 2025
Evert Schimmelpennink(Principal Executive Officer)
/s/ Daniel ChevallardChief Financial OfficerMarch 19, 2025
Daniel Chevallard(Principal Financial and Accounting Officer)
/s/ Jeff GeorgeDirectorMarch 19, 2025
Jeff George
/s/ Frederic GuerardDirectorMarch 19, 2025
Frederic Guerard
/s/ James McCollumDirectorMarch 19, 2025
James McCollum
/s/ Zach ScheinerDirectorMarch 19, 2025
Zach Scheiner
/s/ Shelley ThunenDirectorMarch 19, 2025
Shelley Thunen
/s/ Kimberlee C. DrapkinDirectorMarch 19, 2025
Kimberlee C. Drapkin
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.